全球细胞和基因治疗合约开发和生产组织（CDMO）市场规模、份额、趋势和成长分析报告（2026-2034年）

细胞和基因治疗 CDMO 市场预计将从 2025 年的 74.7 亿美元成长到 2034 年的 340.4 亿美元，2026 年至 2034 年的复合年增长率为 18.36%。

随着製药和生物技术公司越来越多地将复杂的生产流程外包，全球细胞和基因治疗CDMO市场正在快速成长。对癌症、罕见疾病和遗传疾病等先进疗法的投资增加，推动了对专业CDMO的需求。细胞和基因疗法的复杂性需要先进的设施和监管方面的专业知识，这进一步促进了外包伙伴关係的建立。

关键驱动因素包括临床研发管线的扩展和基因修饰疗法监管核准数量的增加。高昂的生产成本和对规模化生产的需求进一步加剧了对经验丰富的合约研发产量机构（CDMO）的依赖。此外，生技公司与CDMO之间的策略合作正在加快产品开发进程并提高供应链效率。

未来，随着病毒载体生产技术、自动化技术和低温运输物流的进步，市场预计将持续扩张。全球临床试验活动的增加和法规结构的支持也将继续为合约研发生产机构（CDMO）创造强劲的发展机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球细胞与基因治疗合约开发与生产（CDMO）市场：依阶段划分

• 市场分析、洞察与预测
• 临床前阶段
• 临床

第五章 全球细胞与基因治疗合约开发与生产（CDMO）市场：依产品类型划分

• 市场分析、洞察与预测
• 基因治疗（体外、体内）
• 基因改造细胞疗法（CAR T 细胞疗法、CAR-NK 细胞疗法、TCR-T 细胞疗法等）
• 细胞疗法

第六章：全球细胞与基因治疗合约开发与生产（CDMO）市场：依适应症划分

• 市场分析、洞察与预测
• 肿瘤学
• 感染疾病
• 神经系统疾病
• 罕见疾病
• 其他的

第七章 全球细胞与基因治疗合约开发与生产（CDMO）市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Lonza
  • Catalent Inc
  • Cytiva
  • Samsung Biologics
  • Thermo Fisher Scientific Inc
  • WuXi AppTec
  • AGC Biologics
  • OmniaBio
  • Charles River Laboratories

The Cell And Gene Therapy CDMO Market size is expected to reach USD 34.04 Billion in 2034 from USD 7.47 Billion (2025) growing at a CAGR of 18.36% during 2026-2034.

The global cell and gene therapy CDMO market is growing rapidly as pharmaceutical and biotechnology companies increasingly outsource complex manufacturing processes. Rising investments in advanced therapies for cancer, rare diseases, and genetic disorders are fueling demand for specialized contract development and manufacturing organizations (CDMOs). The complexity of cell and gene therapies requires advanced facilities and regulatory expertise, encouraging outsourcing partnerships.

Key drivers include expanding clinical pipelines and the growing number of regulatory approvals for gene-modified therapies. High manufacturing costs and the need for scalability further boost reliance on experienced CDMOs. Additionally, strategic collaborations between biotech firms and CDMOs are accelerating product development timelines and improving supply chain efficiency.

In the future, the market is expected to expand with improvements in viral vector production, automation technologies, and cold chain logistics. Increasing global clinical trial activity and supportive regulatory frameworks will continue to create strong opportunities for CDMOs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Phase

• Pre-Clinical
• Clinical

By Product Type

• Gene Therapy (Ex-Vivo, In-Vivo)
• Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other)
• Cell Therapy

By Indication

• Oncology
• Infectious Diseases
• Neurological Disorders
• Rare Diseases
• Others

COMPANIES PROFILED

• Lonza, Catalent Inc, Cytiva, Samsung Biologics, Thermo Fisher Scientific Inc, WuXi AppTec, AGC Biologics, OmniaBio, Charles River Laboratories
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Pre-Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Gene Therapy (Ex-Vivo, In-Vivo) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gene-Modified Cell Therapy (Car T-Cell Therapies, Car-Nk Cell Therapy, Tcr-T Cell Therapy, Other) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Rare Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL AND GENE THERAPY CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Phase
  • 7.2.2 By Product Type
  • 7.2.3 By Indication
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Phase
  • 7.3.2 By Product Type
  • 7.3.3 By Indication
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Phase
  • 7.4.2 By Product Type
  • 7.4.3 By Indication
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Phase
  • 7.5.2 By Product Type
  • 7.5.3 By Indication
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Phase
  • 7.6.2 By Product Type
  • 7.6.3 By Indication
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CELL AND GENE THERAPY CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza
  • 9.2.2 Catalent Inc
  • 9.2.3 Cytiva
  • 9.2.4 Samsung Biologics
  • 9.2.5 Thermo Fisher Scientific Inc
  • 9.2.6 WuXi AppTec
  • 9.2.7 AGC Biologics
  • 9.2.8 OmniaBio
  • 9.2.9 Charles River Laboratories